^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PD

Excerpt:
...- Histologically-proven hormone-receptor positive metastatic breast carcinoma...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Excerpt:
...- Patients must have hormone receptor positive tumors; if there is more than one breast tumor, each tumor must be hormone receptor positive; hormone receptors must be determined using immunohistochemistry; estrogen receptor (ER) and/or progesterone receptor (PgR) must be greater than or equal to 10% of the tumor cells positive by immunohistochemical evaluation; biochemical determination alone is...
Trial ID:
More C2 evidence
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Phase II study of Exemestane dose intensification (150 mg daily) in postmenopausal patients with advanced breast cancer progressing under standard dose Exe (25 mg daily) given as adjuvant or palliative therapy

Excerpt:
...Steroid hormone receptor positive tumours (ER and/or PgR), determined by immunohistochemistry (IHC). ...
Less C2 evidence
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Comparison of a histone deacetylase inhibitor plus exemestane with exemestane alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: A meta-analysis

Published date:
07/18/2022
Excerpt:
Herein, we conducted a meta-analysis to evaluate the efficacy and safety of an HDAC inhibitor plus exemestane vs. exemestane alone in this setting. Our meta-analysis demonstrated that the combination group exhibited significantly prolonged progression-free survival (PFS) [hazard ratio (HR)=0.776, 95% confidence interval (CI)=0.675-0.892, P=0.000] and an improved objective response rate (ORR) (RR=1.612, 95% CI=1.085-2.396, P=0.018) compared to those treated with exemestane alone....In conclusion, the addition of an HDAC inhibitor to exemestane significantly improves PFS over exemestane alone in hormone receptor‑positive ABC patients...
DOI:
10.3892/etm.2022.11512